Prateek Arora

Prateek Arora

Auto-generated profile, based on publicly available information

Prateek Arora

Department of Surgical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2024 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
KKKislay Kant
Kislay Kant
ZAZeeshan Ahmed
Zeeshan Ahmed
RDRohit Dama
Rohit Dama
MKMonish Karunakaran
Monish Karunakaran
PAPrateek Arora
Prateek Arora
GRGuduru Venkat Rao
Guduru Venkat Rao
Kislay Kant, Zeeshan Ahmed, Rohit Dama, Monish Karunakaran, Prateek Arora, Pradeep Rebala, Guduru Venkat Rao. Ann Hepatobiliary Pancreat Surg 2024;28:350-7. https://doi.org/10.14701/ahbps.24-021

26 May 2025 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
ZAZeeshan Ahmed
Zeeshan Ahmed
RTRaviraj Tilloo
Raviraj Tilloo
MKMonish Karunakaran
Monish Karunakaran
SMShreeyash Modak
Shreeyash Modak
PAPrateek Arora
Prateek Arora
GRGuduru Venkat Rao
Guduru Venkat Rao
Zeeshan Ahmed, Raviraj Tilloo, Monish Karunakaran, Shreeyash Modak, Prateek Arora, Sanjeev Patil, Anuradha Sekaran, Mohan Ramchandani, Mahesh Shetty, Rohit Dama, Pradeep Rebala, Guduru Venkat Rao. Ann Hepatobiliary Pancreat Surg -0001;0:. https://doi.org/10.14701/ahbps.25-041

18 January 2025 in Indian Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CHChidananda Harivelam
Chidananda Harivelam
PAPrateek Arora
Prateek Arora
ZAZeeshan Ahmed
Zeeshan Ahmed
MKMonish Karunakaran
Monish Karunakaran
KKKislay Kant
Kislay Kant
GRG. V. Rao
G. V. Rao

3 September 2026 in Journal of Minimal Access Surgery
Verified
Journal Article
Closed access
PAPrateek Arora
Prateek Arora
MGMalinga Gallala
Malinga Gallala
FLFilomena Liccardo
Filomena Liccardo
RFRebecca Fish
Rebecca Fish
LMLorena Martin-Roman
Lorena Martin-Roman
CSChelliah R. Selvasekar
Chelliah R. Selvasekar
Background: Selected high-risk appendiceal neoplasms with tumour perforation or T4 disease may be considered for risk-reducing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), even without overt radiological peritoneal disease. Since 2012, our centre has offered laparoscopic CRS-HIPEC, and a robotic approach was recently introduced to enhance visualisation, dexterity, and precision while minimising surgical trauma. This study evaluates the feasibility, safety, and early outcomes of risk-reducing robotic CRS-HIPEC (RCRS-HIPEC) in selected patients with high-risk appendiceal neoplasms without radiological peritoneal disease. Patients and Methods: This retrospective single-centre case series was conducted at a national referral centre for peritoneal surface malignancy. Eight patients underwent standardised RCRS-HIPEC. The cohort included low-grade appendiceal mucinous neoplasm ( n = 3), goblet cell carcinoma ( n = 4), and appendiceal adenocarcinoma ( n = 1). The standardised operative approach included omentectomy, falciform excision, umbilicectomy, and cholecystectomy or salpingo-oophorectomy where indicated, followed by closed HIPEC. Outcomes assessed included operative time, blood loss, complications, length of stay, histopathology, patient-reported recovery, and preliminary resource utilisation. Results: Mean age was 65.8 years; there were 5 male and 3 female patients. Mean operative time was 6 h 19 min (±25 min), with minimal blood loss (<150 mL). No patient required epidural analgesia, parenteral nutrition, or prolonged critical care. Median time to first flatus was 3 days, and median hospital stay was 5 days. Two patients experienced Clavien–Dindo grade I morbidity, with no major complications. Histopathology demonstrated residual disease in two patients. Early electronic patient-reported outcome measures suggested favourable recovery, and preliminary Patient Level Information and Costing System data indicated potential NHS resource savings. Conclusions: RCRS-HIPEC is feasible and safe in carefully selected patients with high-risk appendiceal neoplasms without radiological peritoneal disease. A standardised robotic approach may promote reproducibility, support enhanced recovery, and reduce healthcare resource use. Larger comparative studies are warranted.

15 October 2026 in Journal of Minimal Access Surgery
Verified
Journal Article
Closed access
PAPrateek Arora
Prateek Arora
AJAseem Jindal
Aseem Jindal
LLLucy Larby
Lucy Larby
LMLorena Martin-Roman
Lorena Martin-Roman
LBLucy Buckley
Lucy Buckley
CSChelliah Selvasekar
Chelliah Selvasekar
Introduction: Robotic surgery offers potential advantages for the surgical management of rectal cancer; however, robust data on its use in locally advanced rectal cancer (LARC) populations are limited. We aimed to evaluate the long-term oncological and perioperative outcomes of robotic surgery in a cohort of patients treated at a single tertiary referral cancer centre. Patients and Methods: In this retrospective study, 105 consecutive patients who underwent robotic surgery for rectal adenocarcinoma between July 2012 and May 2024 at a specialist UK centre were analysed. Patient demographics, tumour characteristics, perioperative outcomes (margin status, complications and conversion rate) and survival (disease-free survival [DFS] and overall survival [OS]) were assessed. Results: The cohort was predominantly male (68.6%) with a median age of 63 (interquartile range 56–70) years. 89.5% of patients had LARC with 53.3% low rectal tumours and 13.3% requiring pelvic exenteration. Neoadjuvant therapy was used in 88.6%. An R0 resection was achieved in 86.7%. The conversion rate to open surgery was low at 0.9%. Clavien–Dindo Grade ≥ III complications occurred in 13.3%, with no 90-day mortality. After a mean follow-up of 53.7 months, the 5-year OS and DFS were 76% and 65%, respectively. Conclusion: Robotic surgery for LARC in a specialised referral setting is safe and feasible, achieving very low conversion rates and zero perioperative mortality. While the R1 and complication rate reflects the cohort’s complexity, it is comparable to benchmarks for advanced pelvic malignancies. These findings endorse the robotic platform for treating challenging rectal cancers within a dedicated multidisciplinary framework.